LONDON (Alliance News) - GlaxoSmithKline PLC on Tuesday said Moncef Slaoui, the chairman of its vaccines division and an executive director, will step down in 2017.
Slaoui will step down from the board at the end of March 2017 and will remain an adviser to the company until the end of June that year. He joined the group in 1988 and became a board member in 2006.
"On behalf of the board, I would like to thank Moncef for his great contribution to the company. He has been personally involved in the discovery and development of some of our most innovative vaccines and spearheaded the overhaul of GSK's pharmaceutical R&D," said Glaxo Chairman Philip Hampton.
Glaxo shares were down 1.1% to 1,401.00 pence Tuesday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.